Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Health and Drug Alerts

Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure

Eric Wooltorton
CMAJ January 22, 2002 166 (2) 219;
Eric Wooltorton
Editorial Fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Health Canada issued an advisory on Nov. 30, 2001,1 after receiving an increasing number of reports of congestive heart failure (CHF), pulmonary edema and pleural effusion suspected to be associated with the diabetic agents rosiglitazone and pioglitazone. Letters to health professionals were also issued by the respective manufacturers, GlaxoSmithKline and Eli Lilly Canada.2,3

Between March 2000 and February 2001, 38 domestic reports of suspected serious adverse drug reactions associated with rosiglitazone were received by the Canadian Adverse Reaction Monitoring Program (CADRMP), including 8 reports of heart failure. In 5 of these cases, the onset of heart failure occurred within 3 days to 6 weeks after rosiglitazone therapy had been started.4

Between August 2000 and August 2001, the CADRMP received 9 reports of serious adverse reactions associated with pioglitazone, including one case of CHF and one of pulmonary edema requiring hospital care; both patients recovered after the therapy was discontinued and appropriate medical therapy instituted.3

There are now changes in the product monographs for both drugs indicating that they should not be prescribed to patients with acute heart failure and that their use should be discontinued if heart failure develops.5,6 As well, the pioglitazone monograph states that patients with New York Heart Association (NYHA) class II cardiac functional status or worse should not receive the drug, and the rosiglitazone monograph states that patients with NYHA class III or IV status should not receive the drug.

The drugs: Both drugs are thiazolidinediones (glitazones) and are used as adjuncts to diet and exercise to reduce insulin resistance in nonpregnant, adult patients with type 2 diabetes mellitus, and in patients with polycystic ovary syndrome. When used alone, neither agent is associated with hypoglycemia.

Rosiglitazone can be used as monotherapy or in combination with metformin or a sulfonylurea. It is not indicated for use with insulin, because unpublished trials have pointed to increased rates of heart failure and other cardiovascular events when the 2 are combined.2

Pioglitazone is to be used as monotherapy. It is not indicated for use in combination with other oral antidiabetic agents or insulin because the safety and efficacy of combination therapy has not been established.6 Unpublished studies indicate that the incidence of edema is higher among patients receiving a combination of pioglitazone and insulin than among those receiving placebo and insulin.7

Both rosiglitazone and pioglitazone are known to be associated with persistent edema, weight gain (due in part to fluid retention and subcutaneous adipose accumulations) and mild anemia. Although no causality of hepatocellular dysfunction has been established for either drug, these medications are contraindicated in patients with active liver disease; liver enzymes should be monitored in other patients because of the association between liver failure and another thiazolidinedione (troglitazone) that is not available in Canada.

Women with polycystic ovary syndrome who take these medications may require contraception, as correction of their insulin insensitivity can lead to resumption of ovulation. The product monographs provide additional details.5,6

What to do: Diabetes is a risk factor for heart disease and CHF. Patients should be warned that thiazolidinedione medications such as rosiglitazone and pioglitazone may lead to the development or exacerbation of CHF. Patients in whom edema, shortness of breath, weight gain, fatigue or weakness develops should seek medical attention promptly. If the symptoms are related to heart failure, thiazolidinedione therapy should be discontinued. Rosiglitazone and pioglitazone should not be prescribed in combination with insulin, and they should not be prescribed to patients with NYHA class II, III or IV cardiac functional status (even though the product monograph for rosiglitazone states that patients with class III or IV cardiac status should not be given the drug5). (Note: Patients with NYHA class II cardiac status have cardiac disease that slightly limits their physical activity; they are comfortable at rest, but ordinary physical activity causes fatigue, palpitations, dyspnea or angina.8)

References

  1. 1.↵
    Important safety reminder for patients taking oral diabetes drugs of the glitazone class, Avandia® and Actos®. Ottawa: Health Canada; 2001 Nov 30. Available: www.hc-sc.gc.ca/english/protection/warnings/2001/2001_132e.htm (accessed 2001 Dec 17).
  2. 2.↵
    Important safety information regarding Avandia® (rosiglitazone maleate). Mississauga (ON): GlaxoSmithKline; 2001 Nov 13. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/avandia_e.html (accessed 2001 Dec 17).
  3. 3.↵
    Important safety information regarding Actos®. Toronto: Eli Lilly Canada Inc.; 2001 Nov 6. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/actos_e.html (accessed 2001 Dec 17).
  4. 4.↵
    McMorran M, Vu D. Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions. Can ADR Newsl 2001;11(3):2-3. Also in CMAJ 2001; 165(1):82-3. Available: www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/publicat/adrv11n3_e.html (accessed 2001 Dec 17).
    OpenUrl
  5. 5.↵
    Avandia®, rosiglitazone maleate tablets [product monograph]. Mississauga (ON): GlaxoSmithKline; 2001 Oct 19.
  6. 6.↵
    Actos® (pioglitazone hydrochloride) tablets [product monograph]. Toronto: Eli Lilly Canada Inc.; 2001 Oct 26.
  7. 7.↵
    Actos® — edema [medical information sheet]. Toronto: Eli Lilly Canada Inc.; 2001 Feb 28.
  8. 8.↵
    Criteria Committee, New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown & Co; 1994. p. 253-6.
PreviousNext
Back to top

In this issue

CMAJ
Vol. 166, Issue 2
22 Jan 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure
Eric Wooltorton
CMAJ Jan 2002, 166 (2) 219;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure
Eric Wooltorton
CMAJ Jan 2002, 166 (2) 219;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease
  • Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003-2009
  • Thiazolidinediones and Heart Failure: A teleo-analysis
  • Rosiglitazone (Avandia) and macular edema
  • Peroxisome Proliferator-Activated Receptors: Vascular and Cardiac Effects in Hypertension
  • Glitazones and Heart Failure: Critical Appraisal for the Clinician
  • Google Scholar

More in this TOC Section

  • Nefazodone (Serzone) withdrawn because of hepatotoxicity
  • Safety updates: repaglinide (GlucoNorm) and bicalutamide (Casodex)
  • Paroxetine (Paxil, Seroxat): increased risk of suicide in pediatric patients
Show more Health and Drug Alerts

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Drugs: hormones & metabolic agents

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire